25million patients worldwide with heart failure, market big enough for multiple devices/treatments for all class levels requiring treatment.
Implulse Dynamics failed its primary endpoint in its US Pivotal IDE Trial but did have positive data in a sub group of patients.
However, since this group was looked at only retrospectively, the FDA is requiring another trial which is currently recruiting.
